OncoPharm

Overview of renal cell carcinoma

Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

This week's episode covers some updates in small cell lung cancer, chemotherapy-induced nausea/vomiting (CINV), SC administration of isatuximab, and Lu-177 vipivotide tetraxetan.

Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

A new drug is approved for ROS1 NSCLC after a prior TKI (with some data in patients after 2 TKIs). Zidesamtinib...easy for you to say.

Also, a post hoc analysis of PACIFIC provides some of the best evidence yet of the detrimental effect (?) of PPI use prior to ICI use.

Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

This week's pod covers some brief updates comparing the timelines of the FDA approvals for daraxonrasib vs. enfortuamb vedodin + pembrolizumab, before devoting the rest of the time to the new approval of gedatolisib, a PIK3CA inhibitor, with fulvestrant and maybe palbociclib if you feel like it for metastatic breast cancer in the 2nd line. Oh, in patients WITHOUT PIK3CA mutations.

Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

Did lenalidomide maintenance in multiple myeloma just get limited to 2 years?

Endurance Trial, Part 2: https://www.nejm.org/doi/full/10.1056/NEJMoa2600157

Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm